Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer

Signal Transduct Target Ther. 2023 Mar 19;8(1):118. doi: 10.1038/s41392-023-01322-w.

Authors

Xiuwen Guan¹, Fei Ma¹, Qiao Li¹, Shanshan Chen¹, Ying Fan¹, Jiayu Wang¹, Yang Luo¹, Pin Zhang¹, Qing Li¹, Binghe Xu²

Affiliations

¹ Department of Medical Oncology and State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
² Department of Medical Oncology and State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. xubinghe@medmail.com.cn.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Acrylamides
Aminoquinolines
Breast Neoplasms* / drug therapy
Breast Neoplasms* / genetics
Capecitabine / therapeutic use
Female
Humans

Substances

Capecitabine
pyrotinib
Acrylamides
Aminoquinolines